FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma

Blood

Volumn 124, Issue 20, 2014, Pages 3118-3129

  Vogel, Marion J ^a   Xie, Linka ^b   Guan, Hanfeng ^b   Tooze, Reuben M ^c,d   Maier, Thomas ^a   Kostezka, Ulrike ^a   Maier, Harald J ^a   Holzmann, Karlheinz ^a   Chan, Fong Chun ^e   Steidl, Christian ^e   Reichel, Jonathan B ^f   Weitzer, Clarissa D ^a   Gehringer, Franziska ^a   Kick, Anita B ^a   Cesarman, Ethel ^f   Roshal, Mikhail ^f,g   Gascoyne, Randy D ^e   Möller, Peter ^a   Wirth, Thomas ^a   Ushmorov, Alexey ^a  

^a UNIVERSITY OF ULM   (Germany)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c UNIVERSITY OF LEEDS   (United Kingdom)

^d ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FKHR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; MYC PROTEIN; PRDM1 PROTEIN, HUMAN; REPRESSOR PROTEIN;

ARTICLE; B LYMPHOCYTE INDUCED MATURATION GENE 1ALPHA; CELL DIFFERENTIATION; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; FOXO1 GENE; GENE EXPRESSION PROFILING; GENE REPRESSION; LYMPHOMA CELL LINE; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; PLASMA CELL; PRIMARY CELL; REED STERNBERG CELL; TUMOR SUPPRESSOR GENE; UPREGULATION; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; HODGKIN DISEASE; HUMAN; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; DOWN-REGULATION; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-MYC; REED-STERNBERG CELLS; REPRESSOR PROTEINS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 84911879240     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-590570     Document Type: Article

References (64)

1. Shaffer AL, Emre NC, Romesser PB, Staudt LM. IRF4: Immunity. Malignancy! Therapy? Clin Cancer Res. 2009;15(9): 2954-2961.
2. Mathas S, Janz M, Hummel F, et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nat Immunol. 2006;7(2):207-215.
3. Buettner M, Greiner A, Avramidou A, Jäck HM, Niedobitek G. Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Hematol Oncol. 2005;23(3-4): 127-132.
4. Steidl C, Diepstra A, Lee T, et al. Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma. Blood. 2012;120(17):3530-3540.
5. Schmitz R, Stanelle J, Hansmann ML, Küppers R. Pathogenesis of classical and lymphocyte-predominant Hodgkin lymphoma. Annu Rev Pathol. 2009;4:151-174.
6. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100(12):2961-2969.
7. Holtick U, Vockerodt M, Pinkert D, et al. STAT3 is essential for Hodgkin lymphoma cell proliferation and is a target of tyrphostin AG17 which confers sensitization for apoptosis. Leukemia. 2005;19(6): 936-944.
8. Rui L, Emre NC, Kruhlak MJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 2010;18(6):590-605.
9. Carbone A, Gloghini A, Aldinucci D, Gattei V, Dalla-Favera R, Gaidano G. Expression pattern of MUM1/IRF4 in the spectrum of pathology of Hodgkin's disease. Br J Haematol. 2002;117(2): 366-372.
10. Saito M, Gao J, Basso K, et al. A signaling pathway mediating downregulation of BCL6 in germinal center B cells is blocked by BCL6 gene alterations in B cell lymphoma. Cancer Cell. 2007; 12(3):280-292.
11. Lam LT, Wright G, Davis RE, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kappaB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701-3713.
12. Schmidlin H, Diehl SA, Blom B. New insights into the regulation of human B-cell differentiation. Trends Immunol. 2009;30(6):277-285.
13. Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012; 120(23):4609-4620.
14. Mandelbaum J, Bhagat G, Tang H, et al. BLIMP1 is a tumor suppressor gene frequently disrupted in activated B cell-like diffuse large B cell lymphoma. Cancer Cell. 2010;18(6):568-579.
15. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6): a000109.
16. Calado DP, Zhang B, Srinivasan L, et al. Constitutive canonical NF-kB activation cooperates with disruption of BLIMP1 in the pathogenesis of activated B cell-like diffuse large cell lymphoma. Cancer Cell. 2010;18(6):580-589.
17. Xie L, Ushmorov A, Leithäuser F, et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood. 2012;119(15):3503-3511.
18. Zhang Y, Gan B, Liu D, Paik JH. FoxO family members in cancer. Cancer Biol Ther. 2011;12(4): 253-259.
19. Lin YC, Jhunjhunwala S, Benner C, et al. A global network of transcription factors, involving E2A, EBF1 and Foxo1, that orchestrates B cell fate. Nat Immunol. 2010;11(7):635-643.
20. Amin RH, Schlissel MS. Foxo1 directly regulates the transcription of recombination-activating genes during B cell development. Nat Immunol. 2008;9(6):613-622.
21. Tang TT, Dowbenko D, Jackson A, et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem. 2002; 277(16):14255-14265.
22. Yang G, Lim CY, Li C, et al. FoxO1 inhibits leptin regulation of pro-opiomelanocortin promoter activity by blocking STAT3 interaction with specificity protein 1. J Biol Chem. 2009;284(6): 3719-3727.
23. Kortylewski M, Feld F, Krüger KD, et al. Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J Biol Chem. 2003;278(7): 5242-5249.
24. Miao H, Zhang Y, Lu Z, Yu L, Gan L. FOXO1 increases CCL20 to promote NF-kB-dependent lymphocyte chemotaxis. Mol Endocrinol. 2012;26(3):423-437.
25. Lin L, Hron JD, Peng SL. Regulation of NF-kappaB, Th activation, and autoinflammation by the forkhead transcription factor Foxo3a. Immunity. 2004;21(2):203-213.
26. Wang J, Sun Q, Morita Y, et al. A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell. 2012; 148(5):1001-1014.
27. Tam W, Gomez M, Chadburn A, Lee JW, Chan WC, Knowles DM. Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. Blood. 2006;107(10): 4090-4100.
28. Guan H, Xie L, Leithäuser F, et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classic Hodgkin lymphoma. Blood. 2010;116(9):1469-1478.
29. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Methods Enzymol. 1983;101: 582-598.
30. Ushmorov A, Leithäuser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood. 2006;107(6):2493-2500.
31. Bohle V, Döring C, Hansmann ML, Küppers R. Role of early B-cell factor 1 (EBF1) in Hodgkin lymphoma. Leukemia. 2013;27(3):671-679.
32. Sagardoy A, Martinez-Ferrandis JI, Roa S, et al. Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 2013; 121(21):4311-4320.
33. Brown P, Marafioti T, Kusec R, Banham AH. The FOXP1 transcription factor is expressed in the majority of follicular lymphomas but is rarely expressed in classical and lymphocyte predominant Hodgkin's lymphoma. J Mol Histol. 2005;36(4):249-256.
34. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 2005;102(43):15545-15550.
35. Lin Y, Wong K, Calame K. Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. Science. 1997;276(5312): 596-599.
36. Yu J, Angelin-Duclos C, Greenwood J, Liao J, Calame K. Transcriptional repression by blimp-1 (PRDI-BF1) involves recruitment of histone deacetylase. Mol Cell Biol. 2000;20(7): 2592-2603.
37. Aldinucci D, Gloghini A, Pinto A, De Filippi R, Carbone A. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol. 2010;221(3):248-263.
38. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer. 2009;9(1):15-27.
39. Seitz V, Thomas PE, Zimmermann K, et al. Classical Hodgkin's lymphoma shows epigenetic features of abortive plasma cell differentiation. Haematologica. 2011;96(6):863-870.
40. Naumovski L, Utz PJ, Bergstrom SK, et al. SUP-HD1: a new Hodgkin's disease-derived cell line with lymphoid features produces interferon-gamma. Blood. 1989;74(8):2733-2742.
41. Györy I, Fejér G, Ghosh N, Seto E, Wright KL. Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines. J Immunol. 2003; 170(6):3125-3133.
42. Mechold U, Gilbert C, Ogryzko V. Codon optimization of the BirA enzyme gene leads to higher expression and an improved efficiency of biotinylation of target proteins in mammalian cells. J Biotechnol. 2005;116(3):245-249.
43. van Boxtel R, Gomez-Puerto C, Mokry M, et al. FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis. Cell Death Differ. 2013;20(9):1219-1229.
44. Vrzalikova K, Vockerodt M, Leonard S, et al. Down-regulation of BLIMP1a by the EBV oncogene, LMP-1, disrupts the plasma cell differentiation program and prevents viral replication in B cells: implications for the pathogenesis of EBV-associated B-cell lymphomas. Blood. 2011;117(22):5907-5917.
45. Iqbal J, Kucuk C, Deleeuw RJ, et al. Genomic analyses reveal global functional alterations that promote tumor growth and novel tumor suppressor genes in natural killer-cell malignancies. Leukemia. 2009;23(6):1139-1151.
46. Nie K, Zhang T, Allawi H, et al. Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. Am J Pathol. 2010;177(3):1470-1479.
47. Nie K, Gomez M, Landgraf P, et al. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol. 2008;173(1):242-252.
48. Liu YY, Leboeuf C, Shi JY, et al. Rituximab plus CHOP (R-CHOP) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B-cell lymphoma. Blood. 2007; 110(1):339-344.
49. Zhang YW, Xie HQ, Chen Y, et al. Loss of promoter methylation contributes to the expression of functionally impaired PRDM1b isoform in diffuse large B-cell lymphoma. Int J Hematol. 2010;92(3):439-444.
50. Ocaña E, González-García I, Gutiérrez NC, Mora-López F, Brieva JA, Campos-Caro A. The expression of PRDI-BF1 beta isoform in multiple myeloma plasma cells. Haematologica. 2006; 91(11):1579-1580.
51. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories: Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol. 2010;11(2):114-120.
52. Dengler HS, Baracho GV, Omori SA, et al. Distinct functions for the transcription factor Foxo1 at various stages of B cell differentiation. Nat Immunol. 2008;9(12):1388-1398.
53. Omori SA, Cato MH, Anzelon-Mills A, et al. Regulation of class-switch recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity. 2006;25(4): 545-557.
54. Tooze RM. A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit. Front Immunol. 2013;4:460.
55. Mestas J, Hughes CC. Of mice and not men: differences between mouse and human immunology. J Immunol. 2004;172(5):2731-2738.
56. Shaffer AL, Lin KI, Kuo TC, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17(1):51-62.
57. Ozaki K, Spolski R, Ettinger R, et al. Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol. 2004;173(9):5361-5371.
58. Diehl SA, Schmidlin H, Nagasawa M, et al. STAT3-mediated up-regulation of BLIMP1 Is coordinated with BCL6 down-regulation to control human plasma cell differentiation. J Immunol. 2008;180(7): 4805-4815.
59. Hangaishi A, Kurokawa M. Blimp-1 is a tumor suppressor gene in lymphoid malignancies. Int J Hematol. 2010;91(1): 46-53.
60. Huang X, Zhou X, Wang Z, et al. CD99 triggers upregulation of miR-9-modulated PRDM1/BLIMP1 in Hodgkin/Reed-Sternberg cells and induces redifferentiation. Int J Cancer. 2012;131(4):E382-E394.
61. Gan B, Lim C, Chu G, et al. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010; 18(5):472-484.
62. Kress TR, Cannell IG, Brenkman AB, et al. The MK5/PRAK kinase and Myc form a negative feedback loop that is disrupted during colorectal tumorigenesis. Mol Cell. 2011;41(4): 445-457.
63. Vrzalikova K, Woodman CB, Murray PG. BLIMP1a, the master regulator of plasma cell differentiation is a tumor supressor gene in B cell lymphomas. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012;156(1):1-6.
64. Vrzalikova K, Leonard S, Fan Y, et al. Hypomethylation and over-expression of the beta isoform of BLIMP1 is induced by Epstein-Barr virus infection of B cells; potential implications for the pathogenesis of EBV-associated lymphomas. Pathogens. 2012;1(2):83-101.